Lee et al. evaluated the clinical utilities of AFP and PIVKA-II levels as predictors of treatment outcomes in patients with advanced HCC receiving HAIC (n = 60) or CCRT (n = 67) [23]. Here, AFP is linked to hepatocellular carcinoma.